KilgourMD has released significant findings from an independent Phase II clinical trial assessing its hair loss treatment system, specifically designed for menopausal women. Conducted over four months, the study focused on 43 participants experiencing androgenetic alopecia, a common but often neglected condition among this demographic.
The trial’s results show a notable advancement in hair regrowth and reduced hair shedding, marking a potential breakthrough in the treatment of menopause-related hair loss. Unlike previous studies, this trial required a clinically significant level of hair loss for eligibility, providing a more accurate representation of the treatment’s effectiveness. The evaluation measures were also objective and dermatologist-evaluated, contrasting with many consumer perception studies typically employed by cosmetic brands.
By the end of the four-month period, findings indicated that 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a benchmark dermatologists recognize as a meaningful visual change. Furthermore, 26% of participants demonstrated a full one-grade improvement. These results are particularly impressive when compared to conventional pharmaceutical treatments like minoxidil or finasteride, which generally take six to twelve months to yield similar outcomes.
Across the study group, participants experienced an average improvement of 11.1% in Ludwig scores within just four months. Additionally, there was a significant reduction in hair shedding, with standardized assessments revealing a 60% decrease in hair loss by month four. This rapid normalization of the hair growth cycle and improved follicular health were evident as early as day 45, where over 95% of participants showed a decline in terminal hair shedding counts.
The regrowth findings were independently graded by two board-certified dermatologists, with high-resolution imaging confirming visible enhancements in hair density and scalp coverage. Consumer-reported outcomes further reinforced the clinical findings, with more than 80% of participants noting improvements in hair density, health, and overall appearance by the conclusion of the study.
Dr. James Kilgour, the board-certified dermatologist and founder of KilgourMD, emphasized the study’s importance, stating, “Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning. This study validates not only the performance of the KilgourMD System but also the importance of designing and testing solutions specifically for this population. These results represent a meaningful step forward in how menopausal hair loss is treated.”
With these promising clinical results, KilgourMD aims to redefine evidence-based hair loss solutions, showcasing the potential for clinically significant regrowth and reduced shedding in a matter of months. The complete study findings are currently undergoing peer review and are anticipated to be published later in the year.
KilgourMD is dedicated to revolutionizing hair care by prioritizing scalp health. Founded by Dr. Kilgour, the brand emerged from a personal connection to the struggles of menopause-related hair loss, aiming to provide effective treatments without the side effects commonly associated with traditional options. Through innovative formulas and proprietary technologies, KilgourMD focuses on both prevention and treatment, promoting long-term scalp health and stronger hair for all genders and hair types.
